Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use
High CD73 expression is associated with development of bone metastases. Zoledronate counteracts this effect. These results suggest that CD73 expression might serve as a biomarker for adjuvant zoledronic acid use.
Authors
- Mikko Mella
- Walter M. Gregory (ORCID: https://orcid.org/0000-0003-2641-8416)
- Arja Jukkola‐Vuorinen (ORCID: https://orcid.org/0000-0002-6107-1764)
- Steven L. Wood
- Katri S. Selander (ORCID: https://orcid.org/0000-0003-4812-294X)
- Ana López-Guajardo
- Janet E. Brown (ORCID: https://orcid.org/0000-0003-4960-3032)
- Jouko Sandholm (ORCID: https://orcid.org/0000-0003-0638-2444)
- Nataliia Petruk (ORCID: https://orcid.org/0000-0003-3130-6750)
- Maria R. Oliva
Institutions
- Åbo Akademi University (FI)
- University of Turku (FI)
- Tampere University (FI)
- Turku Centre for Computer Science (FI)
- Oulu University Hospital (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
- University of Sheffield (GB)
Publication Details
- Journal
- Scientific Reports
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1038/s41598-025-92841-9
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Emil Aaltosen Säätiö
- Biocenter Finland
- Weston Park Cancer Charity